KR20160019032A - Composition for preventing or improving skin anti-aging and anti-wrinkle - Google Patents
Composition for preventing or improving skin anti-aging and anti-wrinkle Download PDFInfo
- Publication number
- KR20160019032A KR20160019032A KR1020140126992A KR20140126992A KR20160019032A KR 20160019032 A KR20160019032 A KR 20160019032A KR 1020140126992 A KR1020140126992 A KR 1020140126992A KR 20140126992 A KR20140126992 A KR 20140126992A KR 20160019032 A KR20160019032 A KR 20160019032A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- daidzein
- composition
- present
- aging
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- 230000003712 anti-aging effect Effects 0.000 title 1
- 230000001153 anti-wrinkle effect Effects 0.000 title 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims abstract description 134
- 230000037303 wrinkles Effects 0.000 claims abstract description 68
- 235000007240 daidzein Nutrition 0.000 claims abstract description 67
- 230000009759 skin aging Effects 0.000 claims abstract description 47
- 239000002537 cosmetic Substances 0.000 claims description 43
- 230000006872 improvement Effects 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 17
- 230000002265 prevention Effects 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 14
- 235000013305 food Nutrition 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000049 pigment Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims 2
- 230000001070 adhesive effect Effects 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 abstract description 16
- 230000032683 aging Effects 0.000 abstract description 12
- 208000024891 symptom Diseases 0.000 abstract description 9
- 230000009467 reduction Effects 0.000 abstract description 7
- KDXVVZMYSLWJMA-UHFFFAOYSA-N Alloimperatorin Chemical compound O1C(=O)C=CC2=C1C(O)=C1OC=CC1=C2CC=C(C)C KDXVVZMYSLWJMA-UHFFFAOYSA-N 0.000 abstract description 4
- 206010040954 Skin wrinkling Diseases 0.000 description 76
- 210000003491 skin Anatomy 0.000 description 72
- 230000000694 effects Effects 0.000 description 38
- 108010035532 Collagen Proteins 0.000 description 30
- 102000008186 Collagen Human genes 0.000 description 30
- 229920001436 collagen Polymers 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 24
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 210000002950 fibroblast Anatomy 0.000 description 17
- 230000004663 cell proliferation Effects 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000000686 essence Substances 0.000 description 6
- -1 pack Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 230000036570 collagen biosynthesis Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 229960000281 trometamol Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- PAFJZWHXMSQJKV-UQZRNVAESA-N (3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol;octadecanoic acid Chemical compound OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.OC[C@@H](O)C1OC[C@H](O)[C@H]1O.CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O PAFJZWHXMSQJKV-UQZRNVAESA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GFVYDNHWTCHDSN-UHFFFAOYSA-N 14-methylpentadecyl octanoate Chemical compound CCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C GFVYDNHWTCHDSN-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000208467 Macadamia Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- BMHFKCFRNXUWKT-UHFFFAOYSA-N hexadecan-7-yl hexanoate Chemical compound C(CCCCC)(=O)OC(CCCCCCCCC)CCCCCC BMHFKCFRNXUWKT-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012747 synergistic agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 피부주름 또는 피부노화 예방; 또는 개선용 조성물에 관한 것이다. 구체적으로, 본 발명은 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 조성물에 관한 것이다.
The present invention relates to a composition for preventing skin wrinkles or skin aging; Or improving composition. Specifically, the present invention relates to the prevention of skin wrinkles or skin aging, including flangenidin and dideoxyne; Or improving composition.
세포외 기질의 주요 구성 성분인 콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포외 간질에 존재하며, 생체 단백질 총 중량의 약 30%를 차지하는 중요한 단백질로서 견고한 3중 나선 구조를 가지고 있다. 특히 뼈와 피부(진피)에 그 포함량이 높으며, 대부분의 다른 체 구조물에서는 섬유상 봉입체로 존재한다. 콜라겐의 주된 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포 접착의 지탱, 세포 분할과 분화의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다.Collagen, a major constituent of the extracellular matrix, is a major substrate protein produced by fibroblasts in the skin. It is present in extracellular epilepsy. It is an important protein that occupies about 30% of the total weight of bioproteins, and has a solid triple helix structure. Especially, it is high in bone and skin (dermis), and it exists as a fibrous inclusion body in most other body structures. The main functions of collagen are known to be mechanical durability of the skin, resistance of connective tissue and binding force of tissue, support of cell adhesion, induction of cell division and differentiation. Such collagen is reduced by aging and photoaging by ultraviolet irradiation, which is known to be closely related to wrinkling of the skin.
종래에는 콜라겐의 주름개선 효과를 이용하기 위하여 화장품 또는 연고 등과 같은 피부외용제 조성물에 콜라겐을 배합한 제품들이 출시되었으나, 이들 제품들은 콜라겐 자체를 피부 표면에 도포하는 것으로 고분자 물질인 콜라겐의 경피 흡수가 어려워 본질적인 주름개선 효과를 나타낼 수 없었다. 이러한 문제를 해결하기 위하여 콜라겐합성 촉진물질에 대한 관심이 높아졌으며, 종래 알려진 콜라겐합성 촉진물질로는 비타민C, 레티노익산, 형질전환생장인자(transforming growth factor, TGF), 동물태반 유래의 단백질(JP8-231370), 베툴린산(betulinic acid, JP8-208424), 클로렐라추출물(JP9-40523, JP10-36283, 섬유아세포 증식 촉진작용) 등이 있다. 그러나 상기 물질은 피부 적용시 자극과 발적 등 안전성 문제로 사용량에 제한이 있거나 그 효과가 미미하여 실질적으로 주름개선 효과를 기대할 수 없다는 문제점이 있다. 따라서 종래 주름개선용 조성물보다 생체에 안전하고 주름개선 효과가 높은 새로운 주름개선 조성물의 개발이 절실히 요구되고 있다.
Conventionally, in order to utilize the wrinkle-reducing effect of collagen, products containing collagen in a composition for external application for skin such as cosmetics or ointment have been marketed. However, these products apply collagen itself to the skin surface, It was not able to exhibit the essential wrinkle-improving effect. To solve this problem, there has been a growing interest in collagen synthesis promoting substances. Examples of known collagen synthesis promoting substances include vitamin C, retinoic acid, transforming growth factor (TGF), animal placenta-derived proteins -231370), betulinic acid (JP8-208424), chlorella extract (JP9-40523, JP10-36283, fibroblast proliferation promoting action) and the like. However, there is a problem in that the use amount of the substance is limited or its effect is insufficient due to safety problems such as irritation and redness in skin application, so that a wrinkle reduction effect can not be expected substantially. Therefore, it is urgently required to develop a novel wrinkle-improving composition which is safer to the living body than the conventional wrinkle-improving composition and has a high wrinkle-reducing effect.
이러한 배경하에, 본 발명자들은 우수한 피부주름 및 피부노화 예방; 또는 개선 효과가 뛰어난 조성물을 개발하기 위한 연구를 수행한 결과, 피부 주름 개선 효과가 있는 다양한 물질 중, 프란게니딘과 주름제거 메커니즘이 서로 다른 다이드제인을 동시에 사용하는 경우 각각 사용하는 경우보다 콜라겐 합성 증진, 섬유아 세포 증식 및 피부주름 개선에 시너지 효과를 나타냄을 규명하여, 이를 활용한 피부주름 및/또는 피부노화 예방; 또는 개선용 조성물을 완성하기에 이르렀다.
Under these circumstances, the present inventors have found that excellent skin wrinkles and prevention of skin aging; The inventors of the present invention conducted a study to develop a composition having excellent effect of improving the skin wrinkles and as a result, it was found that collagenase and collagen removal mechanism, which are different from each other, Synergistic effects on synthetic promotion, fibroblast proliferation and skin wrinkle improvement, and to prevent skin wrinkles and / or skin aging using the same; Or a composition for improvement.
본 발명의 하나의 목적은 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 화장료 조성물을 제공하는 것이다.One object of the present invention is to provide a method for preventing skin wrinkles or skin aging comprising frangenidine and dideoxyne; Or improving cosmetic composition.
본 발명의 다른 목적은 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a method for preventing skin wrinkles or skin aging comprising frangenidine and daidzein; Or improving food composition.
본 발명의 또 다른 목적은 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to prevent skin wrinkles or skin aging including frangerin and daidzein; Or a pharmaceutical composition for therapeutic use.
본 발명의 또 다른 목적은 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to prevent skin wrinkles or skin aging including frangerin and daidzein; Or quasi-quasi-composition for improvement.
본 발명의 또 다른 목적은 프란게니딘 및 다이드제인을 포함하는 조성물을 개체에 투여하는 단계를 포함하는 피부주름 또는 피부노화 예방; 또는 개선 방법을 제공하는 것이다.
Another object of the present invention is to provide a method for preventing skin wrinkles or skin aging comprising administering to a subject a composition comprising flangenidine and a daidzein; Or an improvement method.
상기 과제를 해결하기 위하여, 본 발명의 하나의 양태는 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 화장료 조성물을 제공한다. 본 발명의 상기 조성물은 프란게니딘 또는 다이드제인을 각각 포함하는 화장료 조성물보다 피부주름 또는 피부노화 예방; 또는 개선에 현저한 효과, 즉 시너지적인 효과를 가진다.In order to solve the above-mentioned problems, one aspect of the present invention relates to a method for preventing skin wrinkles or skin aging comprising frangenidine and dideoxyne; Or improving cosmetic composition. The composition of the present invention is more effective than the cosmetic composition comprising flanganidine or daidzein, respectively, to prevent skin wrinkles or skin aging; Or synergistic effect on improvement.
본 발명에서 사용되는 용어 "프란게니딘(prangenidin)"은 C16H14O4의 화학식을 가지며 분자량이 약 270.28인 물질로서, 주름개선 소재로 사용될 수 있다. 종래 주름개선 소재인 레티노익산에 비하여 주름 개선 효과가 뛰어나며, UV에 의한 DNA 손상방지에 탁월한 효과를 가지고 있어 주름 생성의 주요한 요인인 노화 및 광에 의한 주름 생성을 근본적으로 해결할 수 있다. 본 발명의 조성물은 상기 프란게니딘의 화장품학적으로 허용가능한 염을 포함할 수 있다.As used herein, the term " prangenidin "is a material having the formula C 16 H 14 O 4 and having a molecular weight of about 270.28, which can be used as a wrinkle improving material. It has excellent wrinkle-reducing effect as compared with retinoic acid, which is a conventional wrinkle-improving material, and has an excellent effect for preventing DNA damage by UV, which can fundamentally solve aging and wrinkle generation caused by wrinkles. The composition of the present invention may comprise a cosmetically acceptable salt of said flangenidine.
본 발명에서 사용되는 용어 "다이드제인(daidzein)"은 C15H10O4의 화학식을 가지며 분자량이 약 254.24인 이소플라본의 일종으로 대두 추출물로부터 또는 합성으로부터 얻을 수 있다. 또한 갱년기 피부 노화를 개선 또는 예방하는데 우수한 효과를 나타내는 에스트로겐과 구조가 유사하여 피부 주름개선 효과를 가지고 있을 뿐만 아니라 뛰어난 피부 매트릭스 구성성분 합성 능력을 통해 전반적인 피부 상태를 개선해 줄 수 있다. 본 발명의 조성물은 상기 다이드제인의 화장품학적으로 허용가능한 염을 포함할 수 있다.The term " daidzein "as used in the present invention is a type of isoflavone having the formula C 15 H 10 O 4 and having a molecular weight of about 254.24, which can be obtained from soybean extract or from the synthesis. In addition, it is similar in structure to estrogen, which shows excellent effects in improving or preventing skin aging in menopausal age, and has an effect of improving skin wrinkles as well as improving the overall skin condition through excellent skin matrix component composition ability. The composition of the present invention may comprise a cosmetically acceptable salt of the daidzein.
본 발명은 다양한 주름개선 소재를 조합하여 시너지적인 효과를 가지는 조합을 규명하기 위해 노력한 결과, 상기와 같이 주름제거 메커니즘이 서로 다른 프란게니딘과 다이드제인의 시너지적인 효과를 규명하여 완성된 것이다. 따라서 프란게니딘 또는 다이드제인을 각각 포함하는 조성물보다 본 발명의 프란게니딘 및 다이드제인을 모두 포함하는 조성물은 피부주름 또는 피부노화 예방; 또는 개선에 현저한 효과, 즉 시너지적인 효과를 가진다.As a result of efforts to identify combinations having synergistic effects by combining various wrinkle-improving materials, the present invention was completed by identifying the synergistic effects of flangein and daidzein with different wrinkle removal mechanisms as described above. Thus, a composition comprising both the frangerin and daidzein of the present invention over a composition comprising each of the frangerin or daidzein is useful for preventing skin wrinkles or skin aging; Or synergistic effect on improvement.
본 발명에서 용어, "피부 주름"이란, 피부가 쇠하여 생긴 잔줄을 의미하는데, 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐의 감소, 외부 환경 등에 의해 유발될 수 있다.In the present invention, the term "skin wrinkle " means a skin formed by decay of skin, which may be caused by a cause of a gene, a decrease in collagen existing in the skin dermis, or an external environment.
본 발명에서 "피부 주름 예방 또는 개선"이란, 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다.In the present invention, "prevention or improvement of skin wrinkles" refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명에서 용어, "피부 노화"란, 피부에 탄력 감소, 윤기 감소, 주름 생성, 재생력 약화 또는 심한 건조 등의 증상이 나타나는 것으로, 시간의 흐름 또는 외부 환경 등에 의해 유발될 수 있다.The term "skin aging" in the present invention means symptoms such as reduction in elasticity of skin, reduction in gloss, generation of wrinkles, weakening of regenerative power, or severe drying, and may be caused by time or external environment.
본 발명에서 "피부 노화 예방 또는 개선"이란, 상기 노화 증상을 억제 또는 저해하거나, 이미 나타난 노화 증상을 완화시키는 것을 말한다.
In the present invention, "preventing or improving skin aging" refers to inhibiting or inhibiting the aging symptom, or alleviating the symptoms of aging already shown.
피부 섬유아세포의 주된 기능으로 세포외기질 합성과 증식을 통한 손상된 피부 조직 재생 등을 들 수 있는데, 광노화와 같은 외인성노화 요인 또는 유리 산소에 의한 손상 누적, 텔로미어 단절로 인한 세포 노화 등에 따른 내인성 노화 요인들은 진피층 내에 있는 피부섬유아세포의 생리 활성 기능을 저하시키게 된다. 피부 세포외기질 중 95% 이상을 차지하고, 세포의 부착분자(adhesion molecule) 및 세포 골격(cytoskeleton) 등과의 상호 작용과 신호 교류를 통해 섬유아세포의 생리 활성에 매우 주요한 부분을 담당하는 제I형 콜라겐의 합성이 저하될 경우, 피부 조직 내 콜라겐 양이 감소되고, 이에 따라 표면 장력이 감소되어 피부 탄력이 저하되고 피부 주름이 형성될 뿐만 아니라, 세포의 증식 및 재생 기능을 포함하는 생리 활성 기능이 감소하는 악순환의 원인이 된다. 따라서, 피부섬유아세포의 콜라겐은 피부 재생, 피부 탄력, 피부 주름 형성 및 피부 손상 시 조직의 수복 또는 재생과 직접적인 관련이 있다고 볼 수 있다.The major function of dermal fibroblasts is extracellular matrix synthesis and regeneration of injured skin tissue through proliferation. The factors of extrinsic aging such as photoaging, accumulation of damage by free oxygen, and endogenous aging by cell aging due to telomere breakage Reduce the physiological activity of dermal fibroblasts in the dermal layer. Type I collagen, which accounts for more than 95% of the extracellular matrix and plays a major role in the physiological activity of fibroblasts through interactions and signal interactions with adhesion molecules and cytoskeletons of cells, Is reduced, the amount of collagen in the skin tissue is reduced, whereby the surface tension is reduced, so that the skin elasticity is lowered and the skin wrinkles are formed, and the physiological activity including cell proliferation and regeneration is decreased This causes a vicious circle. Therefore, collagen of skin fibroblasts may be directly related to restoration or regeneration of tissue during skin regeneration, skin elasticity, wrinkle formation and skin damage.
즉, 피부 섬유아세포의 콜라겐 또는 프로콜라겐의 합성이 촉진되면, 피부 탄력 개선, 피부 재생, 피부 주름 개선, 상처 치유, 손상된 피부 조직의 수복 및 재생; 및 피부 노화 방지 등의 효과를 얻을 수 있다.
That is, when the synthesis of collagen or procollagen of dermal fibroblast is promoted, improvement of skin elasticity, skin regeneration, improvement of skin wrinkles, wound healing, restoration and regeneration of damaged skin tissue, And prevention of skin aging can be obtained.
따라서 본 발명의 상기 프란게니딘 및 다이드제인을 포함하는 조성물은 콜라겐 합성을 촉진하므로 피부 탄력 증가, 피부 재생, 피부 주름 개선, 상처 치유, 손상된 피부 조직의 수복 및 재생; 및 피부 노화 방지 등의 효과를 가질 수 있다. 구체적으로는 피부주름 또는 피부노화 예방; 또는 개선의 효과를 가질 수 있다.Therefore, the composition comprising the flananidine and daidzein according to the present invention promotes collagen synthesis, thereby increasing skin elasticity, regenerating skin, improving skin wrinkles, healing wounds, restoring and regenerating damaged skin tissues; And prevention of skin aging and the like. Specifically, prevention of skin wrinkles or skin aging; Or an effect of improvement.
또한, 상기 프란게니딘 또는 다이드제인을 각각 포함하는 조성물도 콜라겐 합성 증진, 섬유아세포 증식 및 주름 개선 효과를 나타내지만, 본 발명의 프란게니딘 및 다이드제인을 포함하는 조성물은 시너지 효과에 의한 콜라겐 합성 증진, 섬유아세포 증식 및 주름 개선 효과가 뛰어나므로, 피부주름 또는 피부노화 예방; 또는 개선에 우수한 효과를 가진다.In addition, although compositions each containing the above-mentioned flangenidine or daidzein exhibit the effect of promoting collagen synthesis, fibroblast proliferation and wrinkle improvement, the composition comprising the flangenidine and daidzein of the present invention has a synergistic effect Promoting collagen synthesis, proliferating fibroblasts, and improving wrinkles, thereby preventing skin wrinkles or skin aging; Or has an excellent effect on improvement.
본 발명의 일 실시예에서는 프란게니딘과 다이드제인을 인간 유래 섬유아세포의 배양액에 첨가하여 세포 수준에서 콜라겐 합성 촉진 효과를 실험한 결과, 프란게니딘 및 다이드제인은 함께 사용할 때 각각 사용하는 것보다 세포 수준에서 콜라겐 합성 증진 효과가 더욱 뛰어남을 확인하였다(표 1). In one embodiment of the present invention, the effect of promoting collagen synthesis at the cell level was investigated by adding flangenidin and didezaine to the culture medium of human-derived fibroblasts. As a result, it was found that francidinin and daidzein (Fig. 1). The results are shown in Table 1.
또한, 본 발명의 일 실시예에서는 프란게니딘 및 다이드제인으로 MTT 시험 방법을 수행하여 사람의 섬유아세포증식을 측정한 결과, 프란게니딘 및 다이드제인은 함께 사용할 때 각각 사용하는 것보다 세포 증식 효과가 더욱 뛰어남을 알 수 있었다(표 2).In addition, in one embodiment of the present invention, the MTT assay was conducted with flangenidine and daidzein to measure the proliferation of human fibroblasts. As a result, it was found that, when used together with flanogenidin and daidzein, (Table 2).
또한, 본 발명의 일 실시예에서는 프란게니딘 및 다이드제인을 포함한 로션을 사용하여 주름개선 효과를 측정한 결과, 프란게니딘 또는 다이드제인을 각각 사용한 조성물보다 본 발명에 따른 화장료 조성물이 주름 개선 효과가 더욱 우수함을 확인할 수 있었다(표 6 및 7). In addition, in an embodiment of the present invention, the wrinkle-reducing effect was measured using a lotion containing flangenidine and daidzein. As a result, it was found that the cosmetic composition according to the present invention had wrinkles (Table 6 and 7). ≪ tb > < TABLE >
이를 통해, 본 발명의 화장료 조성물은 프란게니딘과 다이드제인의 시너지 효과에 의한 콜라겐 합성 증진, 섬유아세포 증식 및 주름 개선 효과가 뛰어나므로, 피부주름 또는 피부노화 예방; 또는 개선에 우수한 효과가 있음을 알 수 있었다.Thus, the cosmetic composition of the present invention is excellent in collagen synthesis, fibroblast proliferation and wrinkle-improving effects due to the synergistic effect of flangenidine and daidzein, thereby preventing skin wrinkles or skin aging; It was found that there was an excellent effect on the improvement.
또한, 본 발명의 일 실시예에서는 화장료 조성물의 피부첩포를 통한 피부안전성을 평가한 결과, 본 발명의 화장료 조성물은 프란게니단과 다이드제인의 시너지 효과에 의한 피부주름 또는 피부노화 예방; 또는 개선 효과가 우수할 뿐만 아니라, 동시에 생체에도 안전함을 알 수 있었다(표 8).
In addition, in an embodiment of the present invention, the skin safety of the cosmetic composition was evaluated through skin patches. As a result, the cosmetic composition of the present invention was found to prevent skin wrinkles or skin aging due to synergistic effects of frannidan and daidzein; (Table 8). The results are shown in Table 8, and the results are shown in Table 8.
본 발명의 화장료 조성물 중 다이드제인은 조성물 총 중량 대비 0.0001 내지 10 중량% 포함하여, 구체적으로는 0.0005 내지 5 중량% 포함하며, 더욱 구체적으로는 0.001 내지 1 중량% 포함한다. The cosmetic composition of the present invention contains 0.0001 to 10% by weight, more specifically 0.0005 to 5% by weight, and more specifically 0.001 to 1% by weight based on the total weight of the composition.
상기 함량이 0.0001 중량% 미만이면 본래 목적하는 활성을 충분하게 달성할 수 없어 바람직하지 못하며, 10 중량%를 초과하면 증가하는 함량만큼 뚜렷한 효과의 증대가 기대되지 않아 비경제적이며, 화장료 조성물의 안정성에 문제를 발생시킬 수 있기 때문이다.If the content is less than 0.0001% by weight, the desired activity can not be sufficiently attained, which is not preferable. If the content exceeds 10% by weight, an increase in the effect is not expected to increase markedly. This can cause problems.
또한 프란게니딘은 다이드제인을 포함하는 화장료 조성물의 총 중량 대비 0.0001 내지 10 중량% 포함될 수 있으며, 바람직하게는 0.0005 내지 5 중량%, 더욱 바람직하게는 0.001 내지 1 중량% 포함될 수 있다.Also, frangenidine may be contained in an amount of 0.0001 to 10% by weight, preferably 0.0005 to 5% by weight, more preferably 0.001 to 1% by weight, based on the total weight of the cosmetic composition comprising dideoxane.
상기 함량이 0.0001 중량% 미만일 경우 상기 다이드제인과 시너지 효과를 유발하는 데 어려움이 있어 본 발명의 목적을 달성하기 곤란할 수 있으며, 10 중량%를 초과하는 경우는 증가하는 함량만큼 뚜렷한 효과의 증대가 기대되지 않아 비경제적일 수 있다.
If the content is less than 0.0001% by weight, it may be difficult to achieve the object of the present invention because synergistic effect with the daidzein is difficult to be achieved. When the content exceeds 10% by weight, And can be uneconomical.
또한, 본 발명의 화장료 조성물은 프란게니딘 및 다이드제인의 혼합 비율이 중량 기준으로 1 내지 30:1일 수 있으며, 구체적으로는 1 내지 20:1일 수 있으며, 예를 들어, 1.5:1, 2:1, 10:1 또는 20:1일 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may have a blending ratio of flangenidine and daidzein of 1 to 30: 1 by weight, specifically, 1 to 20: 1, for example, 1.5: 1 , 2: 1, 10: 1, or 20: 1.
본 발명의 일 실시예에서는 프란게니딘 및 다이드제인을 함유하는 로션을 프란게니딘 및 다이드제인의 혼합 비율이 중량 기준으로 2:1 또는 20:1이 되도록 제조하였고(표 3), 상기 로션이 프란게니딘 또는 다이드제인을 각각 함유하는 로션보다 주름 개선 효과가 더욱 우수함을 확인하였다(표 6 및 7).In one embodiment of the present invention, the lotion containing flangenidine and daidzein was prepared such that the mixing ratio of flangenidine and daidzein was 2: 1 or 20: 1 by weight (Table 3) The lotion was found to have a better wrinkle-improving effect than the lotion containing each of the frangerin or daidzein (Tables 6 and 7).
또한, 본 발명의 일 실시예에서는 프란게니딘 및 다이드제인을 함유하는 에센스를 프란게니딘 및 다이드제인의 혼합 비율이 중량 기준으로 1.5:1 또는 10:1이 되도록 제조하였다(표 4).Also, in one embodiment of the present invention, essences containing frangerin and didezane were prepared such that the mixing ratio of flangeridin and didezane was 1.5: 1 or 10: 1 by weight (Table 4) .
또한, 본 발명의 일 실시예에서는 프란게니딘 및 다이드제인을 함유하는 크림을 프란게니딘 및 다이드제인의 혼합 비율이 중량 기준으로 2:1 또는 20:1이 되도록 제조하였다(표 5).
In one embodiment of the present invention, creams containing flangenidine and daidzein were prepared such that the mixing ratio of flangenidine and daidzein was 2: 1 or 20: 1 by weight (Table 5) .
또한, 상기와 같은 본 발명의 화장료 조성물은 필요에 따라 일반 피부화장료에 배합되는 보통의 성분, 예를 들면, 유분, 물, 계면활성제, 보습제, 저급알콜, 증점제, 킬레이트제, 색소, 방부제 및 향료 이루어지는 군에서 선택되는 1종 이상의 성분을 추가로 포함할 수 있으나, 이에 제한되는 것은 아니다.
In addition, the cosmetic composition of the present invention as described above may contain, if necessary, ordinary components to be incorporated in a general skin cosmetic composition such as oil, water, a surfactant, a moisturizer, a lower alcohol, a thickener, a chelating agent, But are not limited to, one or more components selected from the group consisting of
상기와 같은 본 발명의 화장료 조성물의 제형은 특별히 제한되지 않으며, 피부에 사용하는 것으로서, 유연화장수 (영양유액), 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 팩, 피부접착용 패취, 피부접착용 겔, 파우더, 연고, 서스펜션, 에멀젼, 스프레이 또는 미용액 등의 통상의 화장료 형태로 제조될 수 있으며, 이들 각 제형에 적합하고 당 업계에 주지된 각종의 통상적인 담체와 첨가제를 포함할 수 있다. The formulation of the cosmetic composition of the present invention as described above is not particularly limited and may be applied to the skin such as softening longevity (nutritional lotion), convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, pack, Gels, pastes, gels for skin adhesion, powders, ointments, suspensions, emulsions, sprays or essences, and may contain various conventional carriers and additives suitable for each of these formulations and known in the art. have.
상기 영양화장수 및 영양크림은 본 발명의 유효성분 이외에 오일류(스쿠알란 등의 하이드로카본계 오일과 카프릴릭/카프릭 트리글리세라이드, 옥틸도데칸올 등의 에스터계 오일, 올리브오일 등의 내츄럴 오일, 디메치콘, 사이클로펜타실록산 등의 실리콘계 오일 등) 1 내지 20 중량% 및 왁스성분(세틸알코올, 스테아릴알코올, 베헤닐알코올, 밀납, 세레신, 시어버터 등) 1 내지 15 중량%를 함유하도록 제조할 수 있다. 상기 에센스는 본 발명의 유효성분 이외에 다가 알코올류 5 내지 30 중량%를 함유하도록 제조할 수 있다. 상기 마사지 크림은 본 발명의 발효물 이외에 미네랄오일, 이소노닐이소노나노에이트 등의 오일 30 내지 70 중량%를 함유하도록 제조할 수 있다. 상기 팩은 본 발명의 유효성분 이외에 폴리비닐알코올 5 내지 20 중량%를 함유하는 필 오프(peel off) 팩 또는 일반 유화형 화장료에 본 발명의 유효성분 이외에 카올린, 탈크, 산화아연, 이산화티탄 등의 안료가 5∼40 중량% 함유된 워시오프(wash off) 팩으로 제조할 수 있다.The nutritional lotion and nutritional cream may contain, in addition to the active ingredient of the present invention, oils (such as hydrocarbons such as squalane, ester oils such as caprylic / capric triglyceride and octyldodecanol, natural oils such as olive oil, 1 to 20% by weight of a wax component (cetyl alcohol, stearyl alcohol, behenyl alcohol, beeswax, ceresin, shea butter, etc.) 1 to 20% by weight have. The essence may be prepared so as to contain 5 to 30% by weight of polyhydric alcohols in addition to the active ingredient of the present invention. In addition to the fermented product of the present invention, the massage cream may be prepared so as to contain 30 to 70% by weight of an oil such as mineral oil, isononylisononanoate and the like. The pack may contain, in addition to the active ingredient of the present invention, kaolin, talc, zinc oxide, titanium dioxide and the like in addition to the active ingredient of the present invention in peel off packs or general emulsifiable cosmetics containing 5 to 20% by weight of polyvinyl alcohol And a wash off pack containing 5 to 40% by weight of pigment.
또한 상기 화장료 조성물은 화장품, 세제 및 섬유 등의 피부에 접촉하는 피부접촉물질로 제조할 수도 있다.
The cosmetic composition may be prepared from a skin-contacting material such as cosmetics, detergents, and fibers, which is in contact with the skin.
본 발명의 다른 하나의 양태는 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 식품 조성물을 제공한다.Another aspect of the present invention is a method for preventing wrinkles or aging of the skin comprising flangenidine and a daidzein; Or improving food composition.
본 발명에서 사용되는 용어 "프란게니딘", "다이드제인", "피부 주름" 또는 "피부 노화"는 상기에서 서술한 바와 같다.The terms " flangenidin ", "daidzein "," skin wrinkle ", or "skin aging ", as used herein, are as described above.
또한, 상기 식품 조성물은 프란게니딘 및 다이드제인의 식품학적으로 허용가능한 염을 포함할 수 있다.In addition, the food composition may comprise pharmaceutically acceptable salts of flangenide and daidzein.
본 발명의 상기 식품 조성물은 특별히 제한되지 아니하며, 건강 기능 식품 조성물을 포함할 수 있다.The food composition of the present invention is not particularly limited and may include a health functional food composition.
본 발명의 상기 건강 기능 식품 조성물을 식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the composition may be added as it is or may be used together with other food or food ingredients, and may be appropriately used according to a conventional method.
상기 식품의 종류는 특별히 제한되지 아니하며, 통상적인 의미에서의 식품을 모두 포함한다. 상기 물질을 첨가할 수 있는 식품의 비제한적인 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등을 들 수 있다.The kind of the food is not particularly limited, and includes food in a conventional sense. Non-limiting examples of the food to which the substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice creams, , A drink, an alcoholic beverage, and a vitamin complex.
본 발명의 상기 식품 조성물이 음료 조성물인 경우, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 비제한적인 예로 포도당, 과당과 같은 모노사카라이드; 말토스, 수크로오스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 들 수 있다. 상기 첨가되는 추가 성분의 비율은 당업자의 선택에 의해 적절하게 결정될 수 있다.When the food composition of the present invention is a beverage composition, it may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Non-limiting examples of such natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Natural sweetening agents such as dextrin, cyclodextrin; Synthetic sweetening agents such as saccharin and aspartame, and the like. The proportion of the additional component added may be appropriately determined by a person skilled in the art.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강 기능 식품 조성물은 천연 과일 주스, 과일 음료 또는 야채 음료 등의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 사용되거나 2 이상을 조합하여 사용할 수 있다. 이러한 첨가물의 비율 또한 당업자에 의해 적절히 선택될 수 있다.
In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. In addition, the health functional food composition of the present invention may contain pulp for the production of natural fruit juice, fruit drink or vegetable drink. These components may be used independently or in combination of two or more. The ratios of these additives can also be suitably selected by those skilled in the art.
본 발명의 또 다른 하나의 양태는 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 치료용 약학적 조성물을 제공한다.Another aspect of the present invention relates to a method for preventing wrinkles or aging of the skin comprising flangenidine and a daidzein; Or a pharmaceutical composition for therapeutic use.
본 발명에서 사용되는 용어 "프란게니딘", "다이드제인", "피부 주름" 또는 "피부 노화"는 상기에서 서술한 바와 같다.The terms " flangenidin ", "daidzein "," skin wrinkle ", or "skin aging ", as used herein, are as described above.
또한, 상기 약학적 조성물은 프란게니딘 및 다이드제인의 약학적으로 허용가능한 염을 포함할 수 있다.In addition, the pharmaceutical composition may comprise pharmaceutically acceptable salts of flangenidine and daidzein.
본 발명의 상기 약학적 조성물은 약학적으로 허용 가능한 담체를 추가로 포함할 수 있다.The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
본 발명에서, 상기 "약학적으로 허용 가능"하다는 것은, 이를 투여 시 생물체를 자극하지 않으면서, 투여되는 화합물의 생물학적 활성 및 특성을 저해하지 않는, 약학 분야에서 통상적으로 사용되는 것을 의미한다.In the present invention, the above-mentioned "pharmaceutically acceptable" means that it is commonly used in the pharmaceutical field, which does not disturb the biological activity and properties of the compound administered, without irritating the organism upon administration thereof.
본 발명의 상기 약학 조성물은, 상기 담체와 함께 제제화되어, 의약품, 사료 첨가제, 음용수 첨가제 등으로 활용될 수 있다.The pharmaceutical composition of the present invention may be formulated together with the carrier to be used as medicines, feed additives, drinking water additives, and the like.
본 발명에서, 상기 담체의 종류는 특별히 제한되지 아니하며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체의 비제한적인 예로는, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 말토 덱스트린, 글리세롤, 에탄올 등을 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.In the present invention, the type of the carrier is not particularly limited and any carrier conventionally used in the art can be used. Examples of the carrier include, but are not limited to, saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, maltodextrin, glycerol, . These may be used alone or in combination of two or more.
또한, 본 발명의 상기 약학적 조성물은 필요한 경우, 부형제, 희석제, 항산화제, 완충액 또는 정균제 등 기타 약학적으로 허용 가능한 첨가제 들을 첨가하여 사용할 수 있으며, 충진제, 증량제, 습윤제, 붕해제, 분산제, 계면 활성제, 결합제 또는 윤활제 등을 부가적으로 첨가하여 사용할 수 있다.In addition, the pharmaceutical composition of the present invention may be supplemented with other pharmaceutically acceptable additives such as excipients, diluents, antioxidants, buffers or bacteriostats, if necessary, and may be used as fillers, extenders, wetting agents, disintegrants, An activator, a binder, a lubricant, or the like may be additionally used.
본 발명의 상기 약학적 조성물은 경구 투여 또는 비경구 투여를 위한 적합한 다양한 제형으로 제제화되어 사용될 수 있다.The pharmaceutical composition of the present invention may be formulated into various formulations suitable for oral administration or parenteral administration.
상기 경구 투여용 제제의 비제한적인 예로는, 트로키제(troches), 로젠지(lozenge), 정제, 수용성 현탁액, 유성 현탁액, 조제 분말, 과립, 에멀젼, 하드 캡슐, 소프트 캡슐, 시럽 또는 엘릭시르제 등을 들 수 있다.Non-limiting examples of such oral dosage forms include troches, lozenges, tablets, aqueous suspensions, oily suspensions, prepared powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs .
본 발명의 상기 약학 조성물을 경구 투여용으로 제제화하기 위하여, 락토오스, 사카로오스, 솔비톨, 만니톨, 전분, 아밀로펙틴(Amylopectin), 셀룰로오스(Cellulose) 또는 젤라틴(Gelatin) 등과 같은 결합제; 디칼슘 포스페이트(Dicalcium phosphate) 등과 같은 부형제; 옥수수 전분 또는 고구마 전분 등과 같은 붕괴제; 스테아르산 마그네슘(Magnesium stearate), 스테아르산 칼슘(Calcium stearate), 스테아릴 푸마르산 나트륨(Sodium stearyl fumarate) 또는 폴리에틸렌 글리콜 왁스(Polyethylene glycol wax) 등과 같은 윤활유 등을 사용할 수 있으며, 감미제, 방향제, 시럽제 등도 사용할 수 있다.In order to formulate the pharmaceutical composition of the present invention for oral administration, a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose, or gelatin; Excipients such as dicalcium phosphate and the like; Disintegrating agents such as corn starch or sweet potato starch; Lubricants such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax may be used, and sweeteners, fragrances, syrups and the like may also be used. .
나아가 캡슐제의 경우에는 상기 언급한 물질 외에도 지방유와 같은 액체 담체 등을 추가로 사용할 수 있다.Furthermore, in the case of capsules, in addition to the above-mentioned substances, liquid carriers such as fatty oils can be further used.
상기 비경구용 제제의 비제한적인 예로는, 주사액, 좌제, 호흡기 흡입용 분말, 스프레이용 에어로졸제, 연고, 도포용 파우더, 오일, 크림 등을 들 수 있다.Non-limiting examples of the parenteral preparation include injections, suppositories, respiratory inhalation powders, aerosol preparations for spraying, ointments, powder for application, oils, creams and the like.
본 발명의 상기 약학 조성물을 비경구 투여용으로 제제화하기 위하여, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결 건조 제제, 외용제 등을 사용할 수 있으며, 상기 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.In order to formulate the pharmaceutical composition of the present invention for parenteral administration, sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations and external preparations may be used. Examples of the non-aqueous solutions and suspensions include propylene glycol, polyethylene Glycerol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like.
또한, 보다 구체적으로 본 발명의 상기 약학 조성물을 주사액으로 제제화하는 경우, 본 발명의 상기 조성물을 안정제 또는 완충제와 함께 물에서 혼합하여 용액 또는 현탁액으로 제조하고 이를 앰플(ampoule) 또는 바이알(vial)의 단위 투여용으로 제제화할 수 있다. 또한, 본 발명의 상기 약학 조성물을 에어로졸제로 제제화하는 경우, 수분산된 농축물 또는 습윤 분말이 분산되도록 추진제 등이 첨가제와 함께 배합할 수 있다.More specifically, when the pharmaceutical composition of the present invention is formulated into an injection, the composition of the present invention is mixed with water or a stabilizer or buffer in water to prepare a solution or suspension, which is then mixed with an ampoule or a vial Unit dosage form. In addition, when the pharmaceutical composition of the present invention is formulated into an aerosol formulation, a propellant or the like may be added together with the additive such that the water-dispersed concentrate or the wet powder is dispersed.
또한, 본 발명의 상기 약학적 조성물을 연고, 크림 등으로 제제화하는 경우에는, 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화 아연 등을 담체로 사용하여 제제화할 수 있다.When the pharmaceutical composition of the present invention is formulated into an ointment, cream, or the like, it may be an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tracer, a cellulose derivative, a polyethylene glycol, a silicone, a bentonite, Zinc or the like as a carrier.
본 발명의 상기 약학적 조성물의 약학적 유효량, 유효 투여량은 상기 약학 조성물의 제제화 방법, 투여 방식, 투여 시간 및/또는 투여 경로 등에 의해 다양해질 수 있으며, 상기 약학 조성물의 투여로 달성하고자 하는 반응의 종류와 정도, 투여 대상이 되는 개체의 종류, 연령, 체중, 일반적인 건강 상태, 질병의 증세나 정도, 성별, 식이, 배설, 해당 개체에 동시 또는 이시에 함께 사용되는 약물 기타 조성물의 성분 등을 비롯한 여러 인자 및 의약 분야에서 잘 알려진 유사 인자에 따라 다양해질 수 있으며, 당해 기술 분야에서 통상의 지식을 가진 자는 목적하는 치료에 효과적인 투여량을 용이하게 결정하고 처방할 수 있다.The pharmaceutically effective amount and the effective dose of the pharmaceutical composition of the present invention may be varied depending on the formulation method, administration method, administration time and / or route of administration of the pharmaceutical composition, and the reaction to be achieved by the administration of the pharmaceutical composition The type and severity of the subject to be treated, the type of subject to be treated, age, weight, general health condition, symptom or degree of disease, sex, diet, excretion, drugs used simultaneously or simultaneously with the subject, And other factors well known in the medical arts, and those skilled in the art will readily determine and prescribe dosages that are effective for the desired treatment.
본 발명의 상기 약학적 조성물의 보다 바람직한 효과를 위한 투여량은, 구체적으로는 1일 0.1mg/kg 내지 100,000mg/kg, 보다 구체적으로는 1mg/kg 내지 10,000mg/kg일 수 있다. 본 발명의 상기 약학적 조성물의 투여는 하루에 1 회 투여될 수 있고, 수회에 나누어 투여될 수 있다. 따라서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The dose for the more preferable effect of the pharmaceutical composition of the present invention may be specifically from 0.1 mg / kg to 100,000 mg / kg per day, more specifically from 1 mg / kg to 10,000 mg / kg per day. Administration of the pharmaceutical composition of the present invention can be administered once a day, or divided into several doses. Accordingly, the dosage is not limited in any way to the scope of the present invention.
본 발명의 상기 약학적 조성물의 투여 경로 및 투여 방식은 각각 독립적일 수 있으며, 그 방식에 있어 특별히 제한되지 아니하며, 목적하는 해당 부위에 상기 약학 조성물이 도달할 수 있는 한 임의의 투여 경로 및 투여 방식에 따를 수 있다. 상기 약학적 조성물은 경구 투여 또는 비경구 투여 방식으로 투여할 수 있다.The route of administration and the mode of administration of the pharmaceutical composition of the present invention may be independent of each other, and the method is not particularly limited, and any route of administration and administration method may be used as long as the pharmaceutical composition can reach the desired site . The pharmaceutical composition may be administered orally or parenterally.
상기 비경구 투여하는 방법으로는, 예를 들어 정맥 내 투여, 복강 내 투여, 근육 내 투여, 경피 투여 또는 피하 투여 등을 이용할 수 있으며, 상기 조성물을 질환 부위에 도포하거나 분무, 흡입하는 방법 또한 이용할 수 있으나, 이들에 제한되지 아니한다.
The parenteral administration may be, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration or subcutaneous administration, and a method of applying, spraying or inhalation the composition to a diseased site may also be used But are not limited to,
본 발명의 또 다른 하나의 양태는 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 의약외품 조성물을 제공한다.Another aspect of the present invention relates to a method for preventing wrinkles or aging of the skin comprising flangenidine and a daidzein; Or quasi-composition for improvement.
본 발명에서 사용되는 용어 "프란게니딘", "다이드제인", "피부 주름" 또는 "피부 노화"는 상기에서 서술한 바와 같다.The terms " flangenidin ", "daidzein "," skin wrinkle ", or "skin aging ", as used herein, are as described above.
또한, 상기 의약외품 조성물은 프란게니딘 및 다이드제인의 약학적으로 허용가능한 염을 포함할 수 있다.In addition, the quasi-drug composition may comprise pharmaceutically acceptable salts of flangenidine and daidzein.
본 발명의 상기 의약외품 조성물의 제형은 바디 클렌저, 소독 청결제, 세정제, 주방용 세정제, 물티슈, 비누, 핸드 워시 또는 연고제일 수 있으나, 이에 제한되는 것은 아니다.
The formulation of the quasi-drug composition of the present invention may be a body cleanser, a disinfectant cleaner, a detergent, a kitchen detergent, a wet tissue, a soap, a hand wash or an ointment, but is not limited thereto.
본 발명의 또 다른 하나의 양태는 프란게니딘 및 다이드제인을 포함하는 조성물을 개체에 투여하는 단계를 포함하는 피부주름 또는 피부노화 예방; 또는 개선 방법을 제공한다. 구체적으로 상기 조성물은 화장료 조성물, 식품 조성물, 약학적 조성물 및 의약외품 조성물일 수 있다.Another aspect of the present invention is a method for preventing wrinkles or skin aging comprising administering to a subject a composition comprising flangenidine and a daidzein; Or an improvement method. Specifically, the composition may be a cosmetic composition, a food composition, a pharmaceutical composition, and a quasi-drug composition.
본 발명에서 사용되는 용어 "프란게니딘", "다이드제인", "피부 주름" 또는 "피부 노화"는 상기에서 서술한 바와 같다.The terms " flangenidin ", "daidzein "," skin wrinkle ", or "skin aging ", as used herein, are as described above.
본 발명에서 사용되는 용어, "개체"는 쥐, 가축, 인간 등을 포함하는 포유 동물을 비롯한 모든 동물을 의미한다.The term "individual" as used herein refers to all animals, including mammals including rats, livestock, humans, and the like.
본 발명의 상기 피부주름 또는 피부노화 예방; 또는 개선 방법에서, 상기 프란게니딘 및 다이드제인을 포함하는 조성물의 투여량, 투여 경로, 투여 방식 등은 본 발명의 상기 약학적 조성물과 관련하여 상기에서 설명한 바와 동일하다.
Prevention of skin wrinkles or skin aging of the present invention; Or improvement method of the present invention, the dose, route of administration, mode of administration and the like of the composition comprising the above-mentioned frangerin and daidzein are the same as those described above in connection with the pharmaceutical composition of the present invention.
본 발명의 프란게니딘 및 다이드제인을 포함하는 조성물은 프란게니딘 또는 다이드제인을 각각 사용할 때보다 나이가 들수록 여성의 피부에 나타날 수 있는 노화 증상을 예방 및/또는 개선하는 데에 시너지 효과를 가지며, 또한 피부 노화로 인해 유발될 수 있는 다양한 피부노화 증상들 즉, 탄력 감소, 윤기 감소, 주름 생성, 심한 건조감 등의 증상을 예방 및/또는 개선하는 데에도 시너지 효과를 가진다.
The compositions comprising flangenidine and daidzein of the present invention are useful as synergistic agents for preventing and / or ameliorating the symptoms of aging which may appear on the skin of a woman as it is older than when using flangenidine or daidzein, And synergistic effects in preventing and / or ameliorating various symptoms of skin aging which may be caused by aging of the skin, such as elasticity reduction, gloss reduction, wrinkle formation and severe dry feeling.
이하, 본 발명을 보다 구체적으로 설명하기 위하여 하기 실시예 등을 들어 설명한다. 그러나 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며 본 발명의 범위가 아래에서 상술하는 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 본 발명의 구체적 이해를 돕기 위해 예시적으로 제공되는 것이다.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the embodiments described below. The embodiments of the present invention are provided by way of example to facilitate a specific understanding of the present invention.
실험예Experimental Example
1. 콜라겐 합성 효과 1. Collagen synthesis effect
피부 노화예방 및 주름개선 효과가 있는 프란게니딘과 다이드제인을 인간 유래 섬유아세포의 배양액에 첨가하여 세포 수준에서 콜라겐 합성 촉진 효과를 실험하였다. 생합성된 콜라겐 측정은 POCP EIA kit(Procollagen Type I C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다.The effect of promoting collagen synthesis at the cellular level was investigated by adding flangenidin and daidzein, which have the effects of preventing skin aging and improving wrinkles, to human fibroblasts. The biocompatible collagen was quantitated using the POCP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit).
프란게니딘과 다이드제인은 각각 최종 농도가 0.5μg/mL가 되도록 인간 유래 섬유아세포의 배양 배지에 첨가하여 1일간 배양하였다. 배양액을 취하여 PECP EIA kit로 각 농도에서 콜라겐 생합성 정도를 분광광도계를 이용하여 450nm에서 측정하였다. 콜라겐 생합성 효과를 비교하기 위하여 비타민 C를 첨가한 배양액과 추출물을 포함하지 않은 대조군에서도 상기와 동일하게 시험하여 측정하였다. 콜라겐 생합성능은 대조군(무첨가)에 대한 상대적인 합성능으로 계산하였으며, 그 결과를 하기 표 1에 나타내었다. 실험값은 6회 반복하여 실시한 평균값이다.
Francogenidin and daidzein were added to the culture medium of human-derived fibroblasts to a final concentration of 0.5 μg / mL, respectively, and cultured for 1 day. The amount of collagen biosynthesis at each concentration was measured by PECP EIA kit at 450 nm using a spectrophotometer. In order to compare the effect of collagen biosynthesis, the test was carried out in the same manner as described above in the culture medium to which vitamin C was added and the control group which did not contain the extract. The collagen biosynthesis performance was calculated as the relative performance relative to the control (no addition), and the results are shown in Table 1 below. The experimental value is an average value obtained by repeating the experiment six times.
상기 표 1에 나타낸 바와 같이, 2.0μg/mL 프란게니딘을 사용한 경우 콜라겐 합성 증가율이 43%이고, 2.0μg/mL 다이드제인을 사용한 경우 콜라겐 합성 증가율이 30%인 반면, 프란게니딘 1.0μg/mL 및 다이드제인 1.0μg/mL를 함께 사용한 경우 콜라겐 합성 증가율이 54%로 각각 사용한 경우보다 콜라겐 합성 증가율에 현저한 효과를 보였다. 또한 이는 양성 대조군으로 사용한 비타민 C 52.8μg/mL의 콜라겐 합성 증가율보다 2배 이상 큰 수치였다.As shown in the above Table 1, when 2.0 μg / mL flanganin was used, the collagen synthesis increase rate was 43%. When 2.0 μg / mL dideoxan was used, the collagen synthesis increase rate was 30%, while francidinine 1.0 μg / mL and 1.0 μg / mL of daidzein were used together, the increase of collagen synthesis was remarkably more effective than the increase of collagen synthesis rate of 54%, respectively. It was also twice as high as the 52.8 μg / mL increase in collagen synthesis in vitamin C used as a positive control.
이를 통해, 본 발명의 화장료 조성물에 사용되는 프란게니딘 및 다이드제인은 함께 사용할 때 각각 사용하는 것보다 세포 수준에서 콜라겐 합성 증진 효과가 더욱 뛰어남을 알 수 있었다. As a result, it was found that the collagen synthesis enhancing effect at the cellular level was superior to that of each of frangenidine and daidzein used in the cosmetic composition of the present invention.
즉, 본 발명의 화장료 조성물은 프란게니딘과 다이드제인의 시너지 효과에 의한 콜라겐 합성 증진 효과가 뛰어나므로, 피부주름 또는 피부노화 예방; 또는 개선에 우수한 효과가 있음을 알 수 있었다.
That is, the cosmetic composition of the present invention is excellent in the effect of promoting collagen synthesis by synergistic effects of flangenidin and daidzein, so that it prevents skin wrinkles or skin aging; It was found that there was an excellent effect on the improvement.
실험예Experimental Example
2. 세포 증식 효과 2. Cell proliferation effect
피부주름 및 피부노화 예방; 또는 개선 효과가 있는 프란게니딘과 다이드제인의 세포 증식 효과를 측정하기 위하여 사람의 섬유아세포를 96 웰 플레이트에 접종하여 배양한 다음, 프란게니딘 및 다이드제인을 각각 0.1 중량%, 0.05 중량%, 0.01 중량%, 0.005 중량%의 농도로 2일간 적용하고, MTT 시험 방법을 수행하여 세포증식을 평가하였다. 이때, 대조군으로는 무혈청 배지를 사용하였으며, 비교군으로는 혈청(serum) 1%를 부가하여 사용하였다. 프란게니딘과 다이드제인은 비교군과 마찬가지로 무혈청 배지에 적용하였으며, 결과는 표 2에 나타내었다.
Prevention of skin wrinkles and skin aging; Human fibroblasts were inoculated on 96-well plates and cultured. Then, frangenidin and didezain were added to the cells in a concentration of 0.1% by weight, 0.05% by weight %, 0.01% by weight, 0.005% by weight for 2 days and MTT test method was performed to evaluate cell proliferation. At this time, serum-free medium was used as a control group, and 1% of serum was used as a comparative group. Frangeridin and daidzein were applied to serum-free medium as in the comparative group, and the results are shown in Table 2.
상기 표 2에 나타낸 바와 같이, 0.1% 프란게니딘을 사용한 경우 세포증식율이 67%이고, 0.1% 다이드제인을 사용한 경우 세포증식율이 61%인 반면, 프란게니딘 0.05% 및 다이드제인 0.05%를 함께 사용한 경우 세포증식율이 84%로 각각 사용한 경우보다 세포증식율에 현저한 효과를 보였다. 또한 이는 양성 대조군으로 사용한 Serum 1%의 세포증식율보다 2배 이상 큰 수치였다.As shown in Table 2 above, the cell proliferation rate was 67% when 0.1% flangenidine was used, the cell proliferation rate was 61% when 0.1% daidzein was used, while 0.05% of francidin and 0.05% , The cell proliferation rate was significantly higher than that when the cell proliferation rate was 84%, respectively. This was more than twice as high as the cell proliferation rate of 1% Serum used as a positive control.
이를 통해, 본 발명의 화장료 조성물에 사용되는 프란게니딘과 다이드제인은 세포증식을 통한 세포활성 효과가 뛰어남을 확인할 수 있었으며, 프란게니딘 및 다이드제인은 함께 사용할 때 각각 사용하는 것보다 섬유아세포 증식 효과가 더욱 뛰어남을 알 수 있다. As a result, it was confirmed that the francidinin and daidzein used in the cosmetic composition of the present invention were excellent in cell activity through cell proliferation, and franginidin and daidzein were more effective than the respective ones It is found that the cell proliferation effect is more excellent.
즉, 본 발명의 화장료 조성물은 프란게니딘과 다이드제인의 시너지 효과에 의한 섬유아세포 증식 효과가 뛰어나므로, 피부주름 또는 피부노화 예방; 또는 개선에 우수한 효과가 있음을 알 수 있었다.
That is, the cosmetic composition of the present invention is excellent in fibroblast proliferation effect by the synergistic effect of flangenidin and daidzein, so that it prevents skin wrinkles or skin aging; It was found that there was an excellent effect on the improvement.
실시예Example
및 And
비교예Comparative Example
: 수중유형 : Underwater type
유화물Emulsion
제조 Produce
이하, 본 발명의 이해를 돕기 위하여 추가적으로 바람직한 실시예를 제시하였다. 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. The following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
제형예Formulation Example
1. 로션 1. Lotion
하기의 표 3과 같이 프란게니딘 및 다이드제인을 함유하는 로션을 통상의 방법에 따라 제조하였다. 단위는 중량% 이다.
Lotions containing flangenidine and daidzein were prepared according to the conventional method as shown in Table 3 below. The unit is weight%.
제형예Formulation Example
2. 에센스 2. Essence
하기의 표 4와 같이 프란게니딘 및 다이드제인을 함유하는 에센스를 통상의 방법에 따라 제조하였다. 단위는 중량% 이다.
As shown in Table 4 below, essences containing frangerin and daidzein were prepared according to a conventional method. The unit is weight%.
캐스터오일 FAGE-40 Hydrogenated
Castor oil
아크릴레이트크로스폴리머Acrylate / C10-30 alkyl
Acrylate crosspolymer
제형예Formulation Example
3. 크림 3. Cream
하기의 표 5와 같이 프란게니딘 및 다이드제인을 함유하는 크림을 통상의 방법에 따라 제조하였다. 단위는 중량%이다.
Creams containing francidinine and didezane were prepared according to the conventional method as shown in Table 5 below. The unit is weight%.
디스테아레이트Polyglyceryl-3 methylglucose
Distearate
실험예Experimental Example
3. 주름개선 효과 3. Wrinkle improvement effect
상기 제형예 1에서 실시예 1 내지 2 및 비교예 1 내지 2에서 제조한 로션을 사용하여 주름개선 효과를 측정하였다.The wrinkle-improving effect was measured using the lotion prepared in Examples 1 to 2 and Comparative Examples 1 and 2 in Formulation Example 1 above.
40~60세의 여성 60명을 대상으로 1일 2회씩 실시예 1 내지 2 및 비교예 1 내지 2에서 제조한 화장료 조성물을 눈 주위에 균일하게 도포하였고, 측정부위는 눈가 주름(crow's feet)으로 하여 총 3개월간 실시하였다. 이때, 피시험자의 왼쪽 눈가에는 실시예 1 내지 2의 화장료 조성물을 적용하였고, 오른쪽 눈가에는 비교예 1 내지 2의 화장료 조성물을 적용하여 실시하였다. The cosmetic composition prepared in Examples 1 to 2 and Comparative Examples 1 and 2 was uniformly applied to around 60 eyes of 60 women aged 40 to 60 twice a day and the measurement site was crow's feet For 3 months. At this time, the cosmetic compositions of Examples 1 and 2 were applied to the left eye of the subject, and the cosmetic compositions of Comparative Examples 1 and 2 were applied to the right eye.
3개월 후 주름의 완화정도는 육안판정 및 시료 적용 전과 적용 후의 눈가 주름 주형(replica)을 영상분석법으로 주름의 깊이를 측정하여 평가하였다. 이때, 육안판정 기준은 각각의 기재 도포 대조군과 비교하여 개선없음, 약간의 개선, 중증도 개선, 상당한 개선의 4단계로 판정하고, 그 결과를 하기 표 6 및 표 7에 나타내었다. 하기 표 6의 단위는 명이며, 하기 표 7의 주름깊이의 단위는 μm이다.
After three months, the degree of wrinkle relief was evaluated by visual inspection and by measuring the depth of wrinkles by image analysis before and after application of the sample and after application of the eye wrinkle replica. At this time, the naked eye determination criteria were determined in four stages of no improvement, slight improvement, improvement in severity, and significant improvement as compared with the respective substrate application control groups, and the results are shown in Tables 6 and 7 below. The unit in Table 6 is name, and the unit of pleat depth in Table 7 is μm.
상기 표 6을 통하여, 본 발명에 따른 실시예 1 내지 2의 화장료 조성물은 비교예 1 내지 2의 화장료 조성물과 비교하여 우수한 주름개선 효과를 나타냄을 확인할 수 있었다.
It can be seen from the above Table 6 that the cosmetic compositions of Examples 1 and 2 according to the present invention exhibit an excellent wrinkle-reducing effect as compared with the cosmetic compositions of Comparative Examples 1 and 2.
(90일 경과)After applying the cosmetic composition
(90 days passed)
또한 상기 표 7을 통하여, 본 발명에 따른 1 내지 2의 화장료 조성물은 주름의 깊이가 15.4~19.6% 감소한데 반하여, 비교예 1 내지 2의 화장료 조성물은 6.3~9.2% 감소하였다. 이를 통하여 본 발명에 따른 화장료 조성물이 주름 깊이 감소 효과가 더욱 우수함을 확인할 수 있었다. In addition, through Table 7, the cosmetic compositions of Examples 1 and 2 according to the present invention showed a decrease in the depth of wrinkles by 15.4 to 19.6%, whereas those of Comparative Examples 1 and 2 decreased by 6.3 to 9.2%. As a result, it was confirmed that the cosmetic composition according to the present invention is more effective in reducing the wrinkle depth.
이를 통해, 본 발명의 화장료 조성물은 프란게니딘과 다이드제인의 시너지 효과에 의한 콜라겐 합성 증진, 섬유아세포 증식 및 주름 개선 효과가 뛰어나므로, 피부주름 또는 피부노화 예방; 또는 개선에 우수한 효과가 있음을 알 수 있었다.
Thus, the cosmetic composition of the present invention is excellent in collagen synthesis, fibroblast proliferation and wrinkle-improving effects due to the synergistic effect of flangenidine and daidzein, thereby preventing skin wrinkles or skin aging; It was found that there was an excellent effect on the improvement.
실험예Experimental Example
4. 피부안전성 측정 4. Skin safety measurement
상기 실시예 1, 2, 4, 5 및 비교예 1, 3, 4, 6에서 제조한 화장료 조성물의 피부첩포를 통한 피부안전성을 평가하기 위하여, 화장품에 의한 피부 부작용을 경험한 적이 있었던 총 80명(여자: 56명, 남자: 24명)을 대상으로 하여 피험자의 등에 첩포를 도포한 후, 48시간이 지난 후, 첩포를 제거하고 1시간 내지 2시간 후에 일차 판정을 하고 70시간 및 96시간 후에 최종 판정하여, 그 결과를 표 8에 나타내었다. 피부안정성 %는 피험자수 대비 양성 반응자수의 비율을 나타낸다.
In order to evaluate skin safety through skin patches of the cosmetic composition prepared in Examples 1, 2, 4, and 5 and Comparative Examples 1, 3, 4, and 6, a total of 80 skin- (Female: 56, male: 24), 48 hours after application of the back of the subject, and after 1 hour to 2 hours, the primary determination was made 70 hours and 96 hours later The results are shown in Table 8. < tb >< TABLE > Skin stability% represents the ratio of the number of positive reactants to the number of subjects.
상기 표 8을 통하여, 본 발명에 따른 실시예 1, 2, 4, 5 및 비교예 1, 3, 4, 6에서 제조한 화장료 조성물이 모두 유의적으로 피부에 안전함을 확인할 수 있었다.It can be seen from Table 8 that the cosmetic compositions prepared in Examples 1, 2, 4, 5 and Comparative Examples 1, 3, 4, 6 according to the present invention are significantly safe for skin.
이를 통해, 본 발명의 화장료 조성물은 프란게니단과 다이드제인의 시너지 효과에 의한 피부주름 또는 피부노화 예방; 또는 개선 효과가 우수할 뿐만 아니라, 동시에 생체에도 안전함을 알 수 있었다.
Thus, the cosmetic composition of the present invention can prevent skin wrinkles or skin aging due to the synergistic effect of francidenide and daidzein; Or improvement effect, and was also safe for living body.
제형예Formulation Example
4. 음료 4. Beverages
하기 표 9와 같이 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 음료를 통상의 방법에 따라 제조하였다. 단위는 중량%이다.
Prevention of skin wrinkles or skin aging, including frangerin and didezain, as shown in Table 9; Or an improvement drink was prepared according to a conventional method. The unit is weight%.
제형예Formulation Example
5. 5.
캡슐제Capsule
하기 표 10과 같이 프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 캡슐제를 제조하였다.
Prevention of skin wrinkles or skin aging including frangerin and didezain as shown in Table 10 below; Or improving capsules were prepared.
제형예Formulation Example
6. 주사제 6. Injection
프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 치료용 주사제를 제조하였으며, 상세한 조성은 하기 표 11에 나타내었다.
Prevention of skin wrinkles or skin aging, including francidinine and daidzein; Or therapeutic injections were prepared. The detailed compositions are shown in Table 11 below.
제형예Formulation Example
7. 피부 외용연고 7. Ointment for external skin
프란게니딘 및 다이드제인을 포함하는 피부주름 또는 피부노화 예방; 또는 개선용 피부 외용연고의 제형을 제조하였으며, 상세한 조성은 하기 표 12에 나타내었다. 단위는 중량%이다.
Prevention of skin wrinkles or skin aging, including francidinine and daidzein; Or ointment for external use was prepared. The detailed composition is shown in Table 12 below. The unit is weight%.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (9)
Prevention of skin wrinkles or skin aging, including francidinine and daidzein; Or improving cosmetic composition.
The cosmetic composition according to claim 1, wherein the cosmetic composition comprises 0.0001 to 10% by weight of the frangerin relative to the total composition, and 0.0001 to 10% by weight of the daidzein relative to the total composition.
The cosmetic composition according to claim 1, wherein the mixing ratio of flananidine and daidzein is 1 to 30: 1 by weight.
The cosmetic composition according to claim 1, wherein the cosmetic composition further comprises at least one component selected from the group consisting of oil, water, a surfactant, a moisturizer, a lower alcohol, a thickener, a chelating agent, a pigment, Composition.
The cosmetic composition according to claim 1, wherein the formulation of the cosmetic composition is selected from the group consisting of softening longevity (nutritional lotion), convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, pack, skin adhesive patch, skin adhesive gel, powder, ointment, , An emulsion, a spray, or a serum.
Prevention of skin wrinkles or skin aging, including francidinine and daidzein; Or improving food composition.
Prevention of skin wrinkles or skin aging, including francidinine and daidzein; Or a pharmaceutically acceptable salt thereof.
Prevention of skin wrinkles or skin aging, including francidinine and daidzein; Or quasi-composition for improvement.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140102394 | 2014-08-08 | ||
| KR20140102394 | 2014-08-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160019032A true KR20160019032A (en) | 2016-02-18 |
| KR102274487B1 KR102274487B1 (en) | 2021-07-09 |
Family
ID=55457960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140126992A KR102274487B1 (en) | 2014-08-08 | 2014-09-23 | Composition for preventing or improving skin anti-aging and anti-wrinkle |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102274487B1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08208424A (en) | 1994-12-20 | 1996-08-13 | Unilever Nv | Cosmetic composition containing betulinic acid |
| JPH08231370A (en) | 1995-02-23 | 1996-09-10 | Taiyo Kagaku Co Ltd | Skin cosmetic |
| KR20090029536A (en) * | 2007-09-18 | 2009-03-23 | 주식회사 엘지생활건강 | Composition for promoting collagen synthesis and cosmetics comprising the same |
| CN102283787A (en) * | 2010-06-18 | 2011-12-21 | 华东师范大学 | Application of daidzein with function of promoting synthetic activity of collagen to cosmetics for removing and preventing crease |
-
2014
- 2014-09-23 KR KR1020140126992A patent/KR102274487B1/en active IP Right Grant
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08208424A (en) | 1994-12-20 | 1996-08-13 | Unilever Nv | Cosmetic composition containing betulinic acid |
| JPH08231370A (en) | 1995-02-23 | 1996-09-10 | Taiyo Kagaku Co Ltd | Skin cosmetic |
| KR20090029536A (en) * | 2007-09-18 | 2009-03-23 | 주식회사 엘지생활건강 | Composition for promoting collagen synthesis and cosmetics comprising the same |
| CN102283787A (en) * | 2010-06-18 | 2011-12-21 | 华东师范大学 | Application of daidzein with function of promoting synthetic activity of collagen to cosmetics for removing and preventing crease |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102274487B1 (en) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180102431A (en) | Cosmetic composition for anti-aging comprising fucosyllactose | |
| MX2011004666A (en) | Compound useful for treating cellulite. | |
| JP2011195473A (en) | Hyaluronic acid-production promotor | |
| KR102139659B1 (en) | Composition for improving the skin | |
| KR20170103518A (en) | Composition for promoting collagen synthesis and enhancing skin moisture | |
| KR101699127B1 (en) | Composition for promoting collagen synthesis and use thereof | |
| KR20160054673A (en) | Composition for promoting synthesis of hyaluronic acid comprising Portulacae Herba extracts and the use thereof | |
| KR101661288B1 (en) | Composition for improving skin | |
| KR20180072379A (en) | Composition for improving skin condition comprising extract of lily bulblet | |
| KR102274487B1 (en) | Composition for preventing or improving skin anti-aging and anti-wrinkle | |
| KR20170025352A (en) | Composition for improving skin | |
| KR102169935B1 (en) | Composition for promoting hyaluronic acid and collagen production, including marigold extract | |
| KR101720712B1 (en) | Composition for improving skin comprising levistilide A | |
| KR101956842B1 (en) | Cosmetic composition for anti-wrinkle and improving collagen synthesis comprising HCURE-1 | |
| KR20180072381A (en) | Composition for improving skin condition comprising extract of Pisum sativum var. arvense (L.) Poir. | |
| KR20170136801A (en) | Composition for improving skin conditions | |
| KR20110017660A (en) | Composition containing extracts of acanthopanax senticosus | |
| KR102204367B1 (en) | Cosmetic compositions for improving skin wrinkle | |
| KR20170099674A (en) | Composition for improving skin | |
| KR20170099669A (en) | Composition for improving skin | |
| KR101629504B1 (en) | Composition for improving skin conditions containing a combination of cytokines | |
| KR20170025370A (en) | Composition for improving skin | |
| KR101656322B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising gardenoside | |
| JP2023529683A (en) | Skin protection or anti-wrinkle composition containing regentide-034 and regentide-041 | |
| KR20170114741A (en) | Composition for improving skin conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |